Dr. Reddy’s Laboratories has announced its US Specialty Business with the launch of Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories located in Bridgewater, NJ.

Promius Pharma, which will initially focus on the branded dermatology market, is based on a platform of strategic licensing initiatives and internal product development activities undertaken over the last several years. Promius Pharma’s product portfolio currently comprises of three in-licensed and co-developed dermatological products that are scheduled to launch within calendar years 2008-09, and a pipeline of topical products being developed at the Integrated Product Development Facility in Hyderabad, India. Promius Pharma’s current portfolio contains innovative topical products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis.

Commenting on the strategic event, GV Prasad, Vice Chairman and CEO of Dr. Reddy’s, said “We are pleased to announce Promius Pharma, our US Specialty Business, a meaningful milestone in our overall strategy of building a sustainable and profitable branded business. We are committed to establishing a leading position in the US dermatology market by providing innovative solutions to patients and physicians that leverage Promius Pharma’s current portfolio and future additions.”

Promius Pharma has assembled a management team with significant experience within the US dermatology market to accelerate Promius into a leading position within the dermatology marketplace. Jeffrey Wasserstein, Executive Vice President of Dr. Reddy’s North America and Promius Pharma, stated, "We are looking to develop a best-in-class company. In order to accomplish this goal, we are bringing together the most talented people from a cross-section of dermatology companies. We have hired a nationally deployed sales force, are currently manufacturing commercial product and are putting the final touches to our launch plans.”